Bioline RX

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. Its pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is a immunotherapy treatment used fro multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

- Appointment adds diverse commercial experience in new product planning, commercialization strategies and launch readiness spanning 13 career launches, including specific expertise in hematopoietic stem cell mobilization - TEL AVIV, Israel , June 16, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that the Company has appointed biopharmaceutical veteran executive Holly W.

BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer

BioLineRx Ltd. (NASDAQ:BLRX ) Q1 2022 Earnings Conference Call May 11, 2022 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Philip Serlin - CEO Mali Zeevi - CFO Conference Call Participants Mark Breidenbach - Oppenheimer John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by.

BioLineRx Ltd. (BLRX) CEO Philip Serlin on Q1 2022 Results - Earnings Call Transcript

- On track to submit New Drug Application to FDA for Motixafortide in stem cell mobilization (SCM) for autologous stem cell transplantation in mid-2022, consistent with prior guidance - - Progressing critical Motixafortide pre-launch activities while maintaining full optionality on commercialization strategies - - Cash and cash equivalents at March 31, 2022 of $50.6 million, sufficient to fund operations, as currently planned, into first half of 2024 - - Management to hold conference call today, May 11, at 10: 00 am EDT - TEL AVIV, Israel , May 11, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the first quarter ended March 31, 2022 and provides a corporate update.

BioLineRx Reports First Quarter 2022 Financial Results and Provides Corporate Update

Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , May 5, 2022 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx to Report First Quarter 2022 Results on May 11, 2022

BioLineRx Ltd. (BLRX) CEO Philip Serlin on Q4 2021 Results - Earnings Call Transcript

TEL AVIV, Israel, March 16, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the fourth quarter and year ended December 31, 2021 and provides a corporate update.

BioLineRx Reports Year-End 2021 Financial Results and Provides Corporate Update

TEL AVIV, Israel, March 10, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX), (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its audited financial results for the year ended December 31, 2021 on Wednesday, March 16, 2022, before the US markets open.

BioLineRx to Report 2021 Annual Results on March 16, 2022

TEL AVIV, Israel, March 3, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced additional positive results from a follow-on pharmacoeconomic study that was performed based on data from the Company's successful Phase 3 GENESIS trial.

BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization

TEL AVIV, Israel, Jan. 24, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company has completed enrollment of the Phase 1/2a study of its innovative intratumoral cancer vaccine candidate, AGI-134, designed to evaluate the safety and biological activity of AGI-134 in patients with unresectable metastatic solid tumors.

BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors

TEL AVIV, Israel, Jan. 18, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ-CM: BLRX) (TASE: BLRX) a late clinical-stage biopharmaceutical company focused on oncology, today announced that the Company has completed a successful pre-New Drug Application (NDA) meeting with the US Food and Drug Administration (FDA) regarding Motixafortide as a novel stem-cell mobilization agent for autologous bone marrow transplantation in multiple myeloma patients.

BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients

TEL AVIV, Israel, Dec. 17, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today provided updates from an oral presentation delivered by Dr. Zachary Crees from the Washington University School of Medicine in St. Louis (WUSTL) at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, which was held December 11-14, 2021, in Atlanta, GA, and virtually.

BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition

TEL AVIV, Israel, Dec. 15, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced establishment of a Scientific Advisory Board (SAB) to provide insight and guidance on the Company's activities in the field of immuno-oncology.

BioLineRx Announces Formation of Immuno-Oncology Scientific Advisory Board (SAB)

BioLineRx Ltd. (BLRX) CEO Philip Serlin on Q3 2021 Results - Earnings Call Transcript

- Positive results from pharmacoeconomic cost effectiveness study of Motixafortide in stem cell mobilization support its use as standard of care in combination with G-CSF - - Pre-NDA meeting with FDA set for mid-December; NDA submission planned for H1 2022 - - Cash and cash equivalents at September 30, 2021 of $62.2 million - - Management to hold conference call today, November 18, at 10:00 am EST - TEL AVIV, Israel, Nov. 18, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended September 30, 2021 and provides a corporate update.

BioLineRx Reports Third Quarter 2021 Financial Results and Provides Corporate Update

TEL AVIV, Israel, Nov. 12, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended September 30, 2021 on Thursday, November 18, 2021, before the US markets open.

BioLineRx to Report Third Quarter 2021 Results on November 18, 2021

TEL AVIV, Israel, Nov. 4, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced an oral presentation and three poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, which is being held December 11-14, 2021 in Atlanta, GA, and virtually.

BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition

TEL AVIV, Israel, Oct. 13, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug Motixafortide as a primary stem cell mobilization (SCM) agent on top of granulocyte colony stimulating factor (G-CSF), versus G-CSF alone, in multiple myeloma patients undergoing autologous stem cell transplantation (ASCT).

BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization

BioLineRx Ltd. (BLRX) CEO Philip Serlin on Q2 2021 Results - Earnings Call Transcript

TEL AVIV, Israel, Aug. 18, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended June 30, 2021 and provides a corporate update.

BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update

TEL AVIV, Israel, Aug. 12, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended June 30, 2021 on Wednesday, August 18, 2021, before the US markets open.

BioLineRx to Report Second Quarter 2021 Results on August 18, 2021

BioNTech SE

Canadian Solar

Danaos

Global Ship Lease

Jumia

Goldman Sachs JUST US Large Cap Equity ETF

Lithium Americas Corp

Pfizer

VanEck Rare Earth/Strategic Metals ETF

SSR Mining

Universal Insurance Hlds

Viatris

Zogenix

Today, we have our "Double Down or Diversify" series. We have 13 new ideas that contributors have chosen for the second half of the contest.

2021 Top Idea Contest - New Ideas

On May 4, the company crossed successfully a crucial hurdle, putting it en-route toward getting an FDA approval as early as next year.

BioLineRx: A Top Candidate For A Takeover Before 2022 Ends

BioLineRx Ltd.'s (BLRX) CEO Phil Serlin on Q1 2021 Results - Earnings Call Transcript

TEL AVIV, Israel, May 26, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended March 31, 2021 and provides a corporate update.

BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate Update

TEL AVIV, Israel, May 20, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended March 31, 2021 on Wednesday, May 26, 2021, before the US markets open.

News for Bioline RX Stock (BLRX)